Posted: February 5, 2013 at 10:41 am
Vampire FaceLift
The Vampire FaceLift Procedure trade; combines the science of hyaluronic acid fillers (ie, Restylane and Juvederm), unipotent stem cells, and beauty to provide a custom designer procedure.
By: AgapeMedical
Continue reading here:
Vampire FaceLift - Video
Posted: February 4, 2013 at 1:08 pm
Posted: February 4, 2013 at 1:43 am
Biomaterial scaffolds_ the crucial step in stem cell treatment of osteoarthritis.mp4
http://www.stemcellsarthritistreatment.com The combination of stem cells plus scaffolds consisting of biologic materials appears to be a logical strategy for tissue engineering. Biomaterials have been defined at the European Society of Biomaterials Conference in 1987 as " non-viable materials used in a medical device, intended to interact with biological systems." What all this means as far as tissue engineering is that using a framework along with stem cells seems to be promising. The logical types of scaffold material are the natural proteins and polysaccharides (sugars) that make up normal connective tissue. These are biocompatible and contain sites where stem cells can congregate. For practical use these materials need to be able to be produced in a consistent manner and they also have to be modified so they provide sufficient mechanical structure to hold up following transplantation. http
By: Nathan Wei
Excerpt from:
Biomaterial scaffolds_ the crucial step in stem cell treatment of osteoarthritis.mp4 - Video
Posted: February 4, 2013 at 1:43 am
Stem Cell Patient Treated With Adult Stem Cell Therapy - Video
Sigrid Zipser, a patient with coronary artery disease and congestive heart failure and no more treatment options seeked out treatment with Vescell stem cell therapy because it was treatment with her own adult stem cells. Producer: VesCell; Creative Commons license: Attribution.
By: rosaryfilms
Original post:
Stem Cell Patient Treated With Adult Stem Cell Therapy - Video - Video
Posted: February 3, 2013 at 8:11 am
Authors: Kurosaki T, Uematsu M, Shimoda K, Suzuma K, Nakai M, Nakamura T, Kitahara T, Kitaoka T, Sasaki H
Abstract
In this experiment, we developed anionic ternary complexes for effective and safe ocular gene delivery. Ternary complexes were constructed by coating plasmid DNA (pDNA)/polyethylenimine (PEI) complex with anionic polymers such as ?-polyglutamic acid (?-PGA) and chondroitin sulfate (CS). The cationic pDNA/PEI complex showed high gene expression on the human retinal pigment epithelial cell line, ARPE-19 cells. The pDNA/PEI complexes, however, also showed high cytotoxicity on the cells and aggregated strongly in the vitreous body. On the other hand, the anionic ternary complexes showed high gene expression on ARPE-19 cells without such cytotoxicity and aggregation. Afte...
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Posted: February 3, 2013 at 8:11 am
Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma.
Int J Oncol. 2013 Mar;42(3):1052-60
Authors: Zhang M, Wang J, Li C, Hu N, Wang K, Ji H, He D, Quan C, Li X, Jin N, Li Y
Abstract
Apoptin is a chicken anemia virus-derived, p53-independent, bcl-2-insensitive apoptotic protein with the ability to specifically induce apoptosis in various human tumor cells, but not in normal cells. To explore the use of apoptin in tumor gene therapy, we assessed a recombinant adenovirus expressing the apoptin protein (Ad-hTERTp-E1a-Apoptin) in order to determine its lethal and growth-inhibitory effects on PC-3 and RM-1 cells in vitro and its antitumor effect on solid tumors in vivo....
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Posted: February 3, 2013 at 8:11 am
It's exceedingly rare when the
California stem cell agency makes the front page of any newspaper.
“Analyst: Stem
cell agency reforms fall short.”
"'There certainly is a gap between
what we recommended and what they responded with,' said Shapiro,
president emeritus at Princeton
University. ' I wish they had moved closer to our
recommendations.'"
“The process would take years, he
said. The first opportunity to get on the ballot, for instance, would
be in the fall of 2014.”
“Shapiro said he stands firmly behind
his committee's report.
"'I think our recommendations sit
together and interrelate to each other well – and should have been
moved along as quickly as possible,' Shapiro said.
"'It might have been helpful if
they indicated to us what they were willing to do and what they
weren't,' he said."
Posted: February 3, 2013 at 8:11 am
The $3 billion California stem cell agency today served up a warmed-over version of a study that would have the
public believe that the research program has had a major economic
impact on the state.
“In the short term, CIRM’s
expenditures are supporting approximately 3,400 jobs and their
innovative efforts have also attracted substantial additional private
and institutional resources to this research arena in California
CIRM’s long-term impact on such critical aspects of the California
economy as state tax revenues and health care costs beyond the
shorter-term and temporary impact of its direct expenditures cannot
be reliably estimated at this point in CIRM’s history."
“No doubt exists that the stem cell
spending has had a beneficial economic impact. But whether it has had
a 'significant' impact on the California economy is in the eye of the
beholder. The state's economy runs to something like $1.7 trillion a
year. If California were a nation, it would rank among one of the
larger economies in the world. The workforce totals around 18
million, making 25,000 jobs statistically less than a hiccup. Keep in
mind as well that CIRM, until 2009, paid the interest on its
borrowing with more borrowed funds, all of which adds to the total
cost of the borrowing, which is about $3 billion on top of the $3
billion CIRM is handing out.”
Posted: February 3, 2013 at 8:11 am
The governing board of the $3 billion
California stem cell agency will remain dominated by “special
interests” even with the adoption of a plan last week responding to
the far-reaching recommendations of a blue-ribbon Institute of
Medicine (IOM) study, a columnist for the Los Angeles Times said today.
“That's because by law, 23 of the 29
members must be representatives of California institutions eligible
for CIRM grants or of disease advocacy groups with their own interest
in steering money toward their particular concerns.
“As a remedy, the panel proposed
eliminating some board slots reserved for grant-receiving
institutions by Proposition
71, the 2004 initiative that created the agency. The idea
was to fill those slots with truly independent members free of any
stake in CIRM funding, even indirectly.”
Hiltzik wrote,
"Thomas told me his proposal dealt
with even perceived conflicts of interest on the board in such
"definitive fashion" that it won't be necessary to bother
the Legislature, much less the voters, with such big changes as
remaking the board with a majority of independent members. He pointed
out, not without some pride, that one board member called his
proposed changes 'draconian.'"
Hiltzik had some praise for Thomas.
“Let's stipulate that Thomas has, in
CIRM terms, moved a mountain by jostling the board even this far.
Since its inception, the board has set records for arrogance. That's
a direct legacy from Proposition 71, which exempted the stem cell
program, uniquely among California government bodies, from any
practical oversight by the Legislature or elected officials.”
“Shapiro told me from his Princeton
office that Thomas' proposals were 'a significant step in the right
direction, which at least indicates that they haven't ignored the
report.' But he doesn't share Thomas' view that voluntary recusals
solve the conflict of interest problem. That can be done, Shapiro
said, only by replacing stake-holding board members with
independents.
"'The more you can reduce the
inherent conflicts, the better off everyone is going to be,' he said.
The board will 'have to go further over time, in my view.'"
“The Shapiro panel said it didn't
find any instances of inappropriate behavior by board members or
specific conflicts, but there are two reasons for that: It didn't
search for any, and Proposition 71 defined certain conflicts out of
existence. The measure states that it's no conflict for a board
member to also be an officer of an academic institution or private
corporation that might be applying for grants.“One of the CIRM board's enduring
self-delusions is that its conflicts of interest are purely a matter
of 'perception.' But there have been documented instances
of favoritism shown to well-connected grant or loan applicants, and
at least one overt attempt by a board member to overturn a rejection
of his institution's project. So much of the board's discussion takes
place behind closed doors or informally that the opportunities for
mutual back scratching are incalculable.
“Thomas' 'draconian' proposals won't
change this state of affairs. Special interests will still dominate
the board. Will barring 13 members from voting on grants while giving
them full rein to participate in discussions really eradicate even
the perception of conflicts? You'd have to be terminally naive to
think so.”
Posted: February 3, 2013 at 8:11 am
The governing board of the $3 billion
California stem cell agency last week fell far short of complying
with the recommendations of a blue-ribbon Institute of Medicine (IOM) study
that the agency itself commissioned to improve its performance.
Source:
Source:
Source:
Source: